Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 255501 | Other Identifier | IRAS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Medical Research Council | OTHER_GOV |
| Camden and Islington NHS Trust | OTHER_GOV |
| Central and North West London NHS Foundation Trust | OTHER |
Not provided
Not provided
Not provided
Not provided
This study will aim to test whether specific neural circuitry changes, proposed on the basis of a neurocognitive model of anxiety, are a mechanism of action for Cognitive Behavioural Therapy (CBT) interventions. This study aims to provide a theoretical model of the neurobiological mechanisms of CBT's therapeutic effect, where there currently is none, and potentially allow for more targeted/specific approaches to anxiety disorders following the identification of key CBT mechanisms. The ultimate aim is to improve the efficacy of CBT, and more generally, psychological interventions for anxiety disorders.
To test the hypothesis that the neural circuitry of the amygdala and prefrontal cortex will respond to CBT, the impact of a course of CBT on cortical-subcortical circuitry will be tested via a case-control study in individuals entering Improving Access to Psychological Therapies (IAPT) services (IAPT step 3; i.e., full CBT) for anxiety disorders and individuals in waiting lists. This design leverages the naturalistic waiting times in the clinical service and does not interfere with treatment as usual. Measures of brain region-specific connectivity and emotion-related behavioural performance will be assessed through testing sessions at the University College London (UCL) Institute of Cognitive Neuroscience and the Birkbeck-UCL Centre for NeuroImaging (BUCNI), involving computerised cognitive/psychological tasks and functional magnetic resonance imaging (fMRI).
The aims are to:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment Group | Participants undergoing a course of Cognitive Behavioural Therapy (CBT) |
| |
| Waiting List Group | Participants on the Waiting List for CBT |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cognitive Behavioural Therapy | Behavioral | In the Cognitive Behavioural Therapy group (N=87), patients will undergo CBT as part of their routine care in Step 3 of the IAPT programme. This will be administered by suitably trained clinicians. The specification of CBT is as recommended by the National Institute for Health and Care Excellence (NICE) guidelines (CG113 - Generalised anxiety disorder and panic disorder in adults: management). In these guidelines, patients are offered on average, 12-15 hourly, weekly sessions of CBT with a trained and competent practitioners. Therapy sessions involve discussions that identify patterns in thinking or behaviours which may be problematic, and therapists and patients work to set goals to reduce these using cognitive techniques. The principle is to teach the patient how to use CBT techniques in their day-to-day life to promote a lasting effect on mental health. We will test patients before (T1) and after (T2) a course of treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| 'Aversive amplification circuit' connectivity | The engagement of the neural circuit of the amygdala, cingulate cortex and prefrontal cortex will be measured via an fMRI analysis technique called a psychophysiological interactions (PPI) analysis. PPI analysis concerns behaviour-specific increases in the relationship across regional brain activity - this means that it can allow one to assess whether two regions (a priori selected ROIs) show increased connectivity during a specific context or behaviour, suggesting a behaviour-specific increase in transfer of information. The output of this analysis will take form of a continuous beta weight - an index of connectivity across two brain regions (amygdala and medial prefrontal cortex), which represents the primary outcome of the study. | Day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Measure | Description | Time Frame |
|---|---|---|
| Cognitive task performance: Loss/risk aversion task | Measures how averse participants are to risk and loss in a mock gambling context | Day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Cognitive task performance: Go/no-go task |
| Measure | Description | Time Frame |
|---|---|---|
| Mood diary | A 'mood diary' will be implemented during the intervention phase which will involve daily self-report rating of mood ('happy', 'anxious' and 'sad') | Day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Individuals entering IAPT services (IAPT step 3; i.e., full CBT) for anxiety disorders
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Emily Lewis | Contact | 02039872331 | emily.lewis.23@ucl.ac.uk | |
| Oliver Robinson | Contact | 02076791150 | o.robinson@ucl.ac.uk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute of Cognitive Neuroscience, University College London | Recruiting | London | WC1N 3AZ | United Kingdom |
The data may also be published as open-access data online. In this case, all personally-identifiable data will be removed such that participants cannot be identified from this open data.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Waiting List | Other | In the control group (N=87), we will test patients who are currently seeking (but not undergoing) treatment before (T1) and after a wait (T2) of equivalent time (i.e. waiting list controls) |
|
Measures approach/avoidance behaviours under threat of shock or safe conditions
| Day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Cognitive task performance: Facial emotional processing task | Measures brain responses to positive, negative and neutral emotions | Day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Cognitive task performance: Emotional face recognition task | Measures brain responses during two distinct memory processes - the encoding (learning) and retrieval (remembering) of information | Day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Cognitive task performance: Visual affective bias task | Measures biases in patients' cognition towards or away from rewarding stimuli | Day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Regional activations during neuroimaging task: Facial emotional processing task | Measures brain responses to positive, negative and neutral emotions | Day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Regional activations during neuroimaging task: Emotional face recognition task | Measures brain responses during two distinct memory processes - the encoding (learning) and retrieval (remembering) of information | Day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Regional activations during neuroimaging task: Visual affective bias task | Measures biases in patients' cognition towards or away from rewarding stimuli | Day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Clinical symptom measure: Generalised Anxiety Disorder Scale (GAD-7) | Measures symptoms of generalised anxiety, scored between 0-21 with higher scores indicating more severe symptoms | Screening, day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Clinical symptom measure: State Trait Anxiety Inventory (STAI) | Measures state and trait anxiety symptoms, scored between 20-80 with higher scores indicating more severe symptoms | Screening, day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Clinical symptom measures: Patient Health Questionnaire (PHQ-9) | Measures depressive symptoms, scored between 0-27 with higher scores indicating more severe symptoms | Screening, day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Clinical symptom measures: Beck's Depression Inventory (BDI) | Measures depressive symptoms, scored between 0-63 with higher scores indicating more severe symptoms | Screening, day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Clinical symptom measures: Catastrophizing questionnaire | Measures catastrophising, scored between 24-120 with higher scores indicating more severe symptoms | Screening, day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Clinical symptom measures: Daily Stress Inventory (DSI) | Measures frequency and impact of daily stresses. Frequency scored between 0-58 and impact scored between 0-6, with higher scores indicating more severe stress | Screening, day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Clinical symptom measures: Behavioural Inhibition/Behavioural Activation Scales (BIS/BAS) | Measures drive, fun-seeking, reward responsiveness and behavioural inhibition. Behavioural inhibition scored between 7-28, drive between 4-16, fun seeking between 4-16, and reward between 5-20, with higher scores indicating higher levels of those behaviours | Screening, day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| Clinical symptom measures: Eysenck Impulsiveness Scale | Measures impulsiveness, venturesomeness and empathy. Impulsivity scored between 0-19, venturesomeness between 0-16, empathy between 0-18, with higher scores indicating higher levels of those traits | Screening, day 0, up to 12 weeks (post-CBT or matched time on waiting list) |
| ID | Term |
|---|---|
| D000098647 | Generalized Anxiety Disorder |
| D001008 | Anxiety Disorders |
| D008224 | Lymphoma, Follicular |
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015928 | Cognitive Behavioral Therapy |
| D014850 | Waiting Lists |
| ID | Term |
|---|---|
| D001521 | Behavior Therapy |
| D011613 | Psychotherapy |
| D004191 | Behavioral Disciplines and Activities |
| D001071 | Appointments and Schedules |
| D009934 | Organization and Administration |
| D006298 | Health Services Administration |
Not provided
Not provided